Floatz logo

Autologous Dendritic Cell-Adenovirus P53 Vaccine

Lung Cancer

H. Lee Moffitt Cancer Center and Research InstitutevaccinePhase 1/2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
65/ 100

Competitive context

304 Active assets in the Lung Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
University of Vermont
Phase 4BB
Carboplatin
SystImmune Inc.
Phase 4BB
Nivolumab
University of Chicago
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB

View all 50 →

Same molecule, other indications

Autologous Dendritic Cell-Adenovirus P53 Vaccine is also rated in:

cutaneous melanomaDormant
CCC
Indicative ·
50 / 100
View asset →
cancer of unknown primary siteDormant
CCC
Indicative ·
50 / 100
View asset →
kidney cancerDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →